Human Clinical Studies - Overview

Prior to producing Alomac, a human clinical trial was performed testing Aloe macroclada (vahona in Malagasy) pills made by a traditional healer in Madagascar. The positive results were published: (https://www.walshmedicalmedia.com/open-access/aloe-macroclada-from-madagascar-triggers-transient-bone-marrow-stem-cell-mobilization-2157-7633-1000287.pdf).

The amount of Aloe macroclada gel in the healer’s vahona pills used in this first trial, a single recommended dose of 3 pills, was estimated to be between 70-100mg. Other ingredients were partially carbonized herbs. These are available in most markets in Madagascar.

A second clinical trial was performed testing pure dried inner leaf gel of Aloe macroclada at 250mg and 750mg. Both results were similarly positive, indicating the lowest effective dosage was at or below 250mg and that the response increased with increasing dose. The data from this trial is being prepared for publication.

A third, 6-month, clinical trial was performed using Aloe macroclada powder and a retail product containing powdered Aloe macroclada, Stemtech International’s product “StemEnhance3”. [Unfortunately, Stemtech declared bankruptcy and the trial was terminated part way through (Stemtech was in legal trouble for having violated multiple trademarks and patents, including use of their product name “StemEnhance3” – nothing to do with the actual product.)] The data from this trial has yet to be published.

It is estimated that the first pills tested (made by a traditional healer) had 70-100mg of the dry equivalent Aloe macroclada gel in 3 pills, the healer’s recommended dose. The graph below uses 100mg for the healer pills. At this time, the recommended minimum dosage is around 100mg, 3 times per day. A higher dose results in a slightly higher quantity of circulating stem cells. Additional studies are needed to better understand the lowest optimal effective dose.

An increase in CD34+ stem cells following Aloe macroclada consumption across three dose levels shows a clear dose-response relationship. Additional stem cell types were also measured. More details about the second clinical trial will be posted in the near future.